Revisiting Seamless 2 3 Trial for GLP 1 Agonist

In this episode of "In the Interim..." we revisit the ground-breaking seamless phase 2/3 clinical trial for the GLP-1 agonist, dulaglutide—better known as Trulicity. We discuss the intricacies of the adaptive trial design, and the unique features that helped expedite development by 12-18 months. Listeners will gain insight into how Bayesian algorithms and innovative statistical methods were pivotal in navigating a complex trial design, benefiting Eli Lilly's pipeline and changing the landscape of diabetes treatment. Key Highlights: —Outline of the trial design and the barriers faced during its inception in 2007-2008. —Explanation of the Clinical Utility Index and its role in adaptive randomization. —The DSMB's role and interaction with Bayesian decision-making models. —Simulation-based design to optimize development efficiencies. —Insights into the predictive power of the trial on weight loss outcomes in subsequent trials. Quotes: —"The trial was run entirely by Bayesian algorithms." – Scott Berry —"They believed this utility function was absolutely the right way to go forward." – Scott Berry For more head to berryconsultants.com.